Navigation Links
At Six Months Post-Launch, Neurologist-Reported Patient Share for Tecfidera Among Relapsing-Remitting Multiple Sclerosis Patients Already Rivals that of Gilenya
Date:12/10/2013

EXTON, Pa., Dec. 10, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that neurologist-reported patient share for Biogen Idec's Tecfidera, the newest oral disease-modifying therapy (DMT) to reach the multiple sclerosis (MS) market, has increased significantly to seven percent among DMT-treated relapsing-remitting MS (RR-MS) patients, compared with one and three months post-launch. At six months post-launch, Tecfidera's patient share already matches that of Novartis's Gilenya, the first oral DMT (which became commercially available three years ago) and surpasses that of Genzyme's Aubagio, the second oral DMT, which launched one year ago. This growth in Tecfidera's patient share is driven by significant growth in volume per prescriber, reflecting widening adoption within individual practices, as well as significant expansion of the prescriber base (80 percent of surveyed neurologists). Patient origination data show a trend towards fewer patients initiating Tecfidera therapy following a treatment gap of two or more months, suggesting that most patients warehoused in anticipation of Tecfidera's launch have already been switched to the therapy at six months post-launch.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The recently published LaunchTrends: Tecfidera (Wave 3) US 2013 report finds that one-fifth of Tecfidera-treated patients have experienced flushing and/or gastrointestinal events according to prescribers, significantly fewer than three months ago. This decrease is likely the result of increased physician and patient experience with the product, allowing for better management of potential side effects. However, tolerability issues continue to be the m
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
3. New silk technology preserves heat-sensitive drugs for months without refrigeration
4. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
5. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
6. Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
7. New technology delivers sustained release of drugs for up to 6 months
8. Cord Blood America Announces 3rd Quarter and Nine Months 2012 Financial Results
9. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
10. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
11. China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Best Sanitizers, Inc., a leader in ... industry, is asking industry professionals to prepare for fall ... E2 soap they’re currently using to the Best Sanitizers’ ... Hand hygiene is critical to fighting cross-contamination and the ... key criteria are identified to evaluate the effectiveness of ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
(Date:8/28/2014)... in spintronics, an electronic which is not only ... on their spin and the spin-related magnetism. Spin-charge ... signals and vice versa. Recently, the research group ... Physics at Johannes Gutenberg University Mainz in collaboration ... has for the first time realised a new, ...
(Date:8/28/2014)... 2014 The ability for organizations to ... will allow individuals to perform at the highest of ... employers looking to compete in this post–recession era. ... trend, as the sector increasingly focuses on the importance ... will have real results on the organization's development and ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... ("NeoStem" or the "Company") (NYSE Amex: NBS ... revenues, global research and development capabilities and operations in ... China adult stem cells, and China pharmaceuticals, announced today ... will present at the Proactive Investors One2One Investor Forum ...
... June 15, 2011 Dr. Huda Y. Zoghbi , ... Institute (NRI) at Texas Children,s Hospital and ... the 2011 Neuroscience Prize of The Peter and Patricia Gruber ... molecular mysteries behind a number of devastating neurological disorders, including ...
... Inc. (NYSE Amex: PTN ), a biopharmaceutical ... and publication of a report on validation of a ... was supported by grants from Palatin. Michael ... and the Weill Medical College of Cornell University, presented ...
Cached Biology Technology:NeoStem to Present at Two Investor Events This Month 2NeoStem to Present at Two Investor Events This Month 3NeoStem to Present at Two Investor Events This Month 4Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 2Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 3Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 4Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 5Baylor College of Medicine and Texas Children's Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize 6Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal 2
(Date:8/28/2014)... and Alaska totaled 515 million board feet in volume ... more than 10 percent compared to the first quarter ... Station reported today. During this same period, West coast ... board feet. , The total value of these log ... million in the same quarter, while the total value ...
(Date:8/27/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... consists of 2,000 shares of common stock and 2,000 ...
(Date:8/27/2014)... have identified a gene that could help scientists engineer ... in the cell membrane of plants that senses changes ... machinery accordingly. , "It,s similar to a thermostat," ... Duke. , The findings, which appear Aug. 28 ... easier to feed the world,s growing population in the ...
Breaking Biology News(10 mins):West coast log exports up, lumber exports down in second quarter of 2014 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Water 'thermostat' could help engineer drought-resistant crops 2
... interactions in which adults with autism converse with a ... skills, according to a novel study presented in ... published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). ... More than half of individuals diagnosed with ...
... , This release is available in ... to herbivore attack. To defend themselves, they have developed ... such as thale cress ( Arabidopsis thaliana ), produce ... Scientists know many different kinds of these molecules; they ...
... siblings with schizophrenia and a genetic mutation linked to major ... cells (iPS cells) using a new and improved "clean" technique. ... , the team confirms the establishment of two new lines ... In Schizophrenia 1, or DISC1. They made the cells using ...
Cached Biology News:Production of mustard oils: On the origin of an enzyme 2Production of mustard oils: On the origin of an enzyme 3Johns Hopkins team creates stem cells from schizophrenia patients 2Johns Hopkins team creates stem cells from schizophrenia patients 3
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
... Polyoxyethylene Lauryl Ether ... 0.02% Kathon Preservative. Surfactant. ... in immunohistochemistry is 1 ... 35 solution added to ...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
MMP-1/8 (H-300)...
Biology Products: